These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

685 related items for PubMed ID: 8497851

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
    Siegbahn A, Ruusuvaara L.
    Thromb Haemost; 1988 Dec 22; 60(3):361-4. PubMed ID: 3149043
    [Abstract] [Full Text] [Related]

  • 3. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M, Scopece S, Gelato AV, Dimonte D, Semeraro N.
    Thromb Haemost; 1997 Apr 22; 77(4):725-9. PubMed ID: 9134650
    [Abstract] [Full Text] [Related]

  • 4. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
    Colucci M, D'Aprile AM, Italia A, Gresele P, Morser J, Semeraro N.
    Thromb Haemost; 2001 Apr 22; 85(4):661-6. PubMed ID: 11341502
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis.
    Robbie LA, Booth NA, Croll AM, Bennett B.
    Thromb Haemost; 1993 Aug 02; 70(2):301-6. PubMed ID: 8236139
    [Abstract] [Full Text] [Related]

  • 8. Fibrinolytic activity in blood is distributed over a cellular and the plasma fraction which can be modulated separately.
    van Giezen JJ, Chung-A-Hing JE, Vegter CB, Bouma BN, Jansen JW.
    Thromb Haemost; 1994 Dec 02; 72(6):887-92. PubMed ID: 7740459
    [Abstract] [Full Text] [Related]

  • 9. Stimulation of tissue-type plasminogen activator synthesis by retinoids in cultured human endothelial cells and rat tissues in vivo.
    Kooistra T, Opdenberg JP, Toet K, Hendriks HF, van den Hoogen RM, Emeis JJ.
    Thromb Haemost; 1991 May 06; 65(5):565-72. PubMed ID: 1908141
    [Abstract] [Full Text] [Related]

  • 10. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
    Watahiki Y, Scully MF, Ellis V, Kakkar VV.
    Thromb Haemost; 1989 Jun 30; 61(3):502-6. PubMed ID: 2508259
    [Abstract] [Full Text] [Related]

  • 11. Whole blood clot lysis in newborns and adults after adding different concentrations of recombinant tissue plasminogen activator (Rt-PA).
    Trusen B, Ries M, Zenker M, Rauh M, Beinder E, Keuper H, Harms D.
    Semin Thromb Hemost; 1998 Jun 30; 24(6):599-604. PubMed ID: 10066156
    [Abstract] [Full Text] [Related]

  • 12. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
    Meijers JC, Middeldorp S, Tekelenburg W, van den Ende AE, Tans G, Prins MH, Rosing J, Büller HR, Bouma BN.
    Thromb Haemost; 2000 Jul 30; 84(1):9-14. PubMed ID: 10928462
    [Abstract] [Full Text] [Related]

  • 13. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.
    Collen D.
    J Cell Biochem; 1987 Feb 30; 33(2):77-86. PubMed ID: 3553213
    [Abstract] [Full Text] [Related]

  • 14. Function of tissue-type plasminogen activator releaser on vascular endothelial cells and thrombolysis in vivo.
    Ueshima S, Matsuno H, Hayashi M, Horibuchi K, Okada K, Fukao H, Uematsu T, Matsuo O.
    Thromb Haemost; 2002 Jun 30; 87(6):1069-74. PubMed ID: 12083488
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G, Pascucci C, Nenci GG, Mele A, Bürgi R, Heim J.
    Thromb Haemost; 1993 Aug 02; 70(2):294-300. PubMed ID: 8236138
    [Abstract] [Full Text] [Related]

  • 17. Marked impairment of protease-activated receptor type 1-mediated vasodilation and fibrinolysis in cigarette smokers: smoking, thrombin, and vascular responses in vivo.
    Lang NN, Gudmundsdóttir IJ, Boon NA, Ludlam CA, Fox KA, Newby DE.
    J Am Coll Cardiol; 2008 Jul 01; 52(1):33-9. PubMed ID: 18582632
    [Abstract] [Full Text] [Related]

  • 18. Effect of standard heparin and a low molecular weight heparin on thrombolytic and fibrinolytic activity of single-chain urokinase plasminogen activator in vitro.
    Lourenço DM, Dosne AM, Kher A, Samama M.
    Thromb Haemost; 1989 Nov 24; 62(3):923-6. PubMed ID: 2556812
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.